This is a Phase 1b, prospective, randomized, double-blind, placebo-controlled, single-dose,
multicenter, safety study of FX-322, administered by intratympanic injection, in adults with
severe sensorineural hearing loss.
This is a Phase 1b placebo-controlled, double-blind, single-dose safety study of
intratympanic FX-322 dosed in subjects with severe sensorineural hearing loss.
Approximately 30 subjects are planned to be enrolled in this study. The subjects will be
randomized to receive one dose FX-322 (24) or placebo (6) and will return for safety,
otologic, and audiologic assessments at Days 30 and 90 after the study injection.
Sudden hearing loss,
Sensorineural hearing loss,
Auditory Loss and Deafness,
noise-induced hearing loss
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.